Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alnylam Pharmaceuticals (LTS:0HD2) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Alnylam Pharmaceuticals Forward PE Ratio Related Terms
Alnylam Pharmaceuticals Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals Forward PE Ratio Chart
Alnylam Pharmaceuticals Annual Data
Trend
2025-12
Forward PE Ratio
58.69
Alnylam Pharmaceuticals Quarterly Data
2025-09
2025-12
2026-03
Forward PE Ratio
84.14
58.69
46.35
LTS:0HD2 vs ONC, RVMD, RPRX: Forward PE Ratio Comparison
For the Biotechnology subindustry, Alnylam Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alnylam Pharmaceuticals Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's Forward PE Ratio falls into.
Alnylam Pharmaceuticals Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Alnylam Pharmaceuticals (LTS:0HD2) has a Forward PE Ratio of 38.33 as of Jul. 27, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Alnylam Pharmaceuticals and its competitors. According to the industry distribution chart, Alnylam Pharmaceuticals ranks #234 out of 353 companies in the Biotechnology industry, placing it in the top 66.3%.
Is Alnylam Pharmaceuticals' Forward PE Ratio too high?
Alnylam Pharmaceuticals' current Forward PE Ratio is 38.33. The Biotechnology industry median Forward PE Ratio is 22.00. Alnylam Pharmaceuticals' value of 38.33 is 74.2% above this industry median. Based on the distribution chart, Alnylam Pharmaceuticals ranks #234 out of 353 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alnylam Pharmaceuticals has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Forward PE Ratio compare to ONC and RVMD?
According to the Biotechnology industry distribution chart, Alnylam Pharmaceuticals ranks #234 out of 353 companies for Forward PE Ratio. This places Alnylam Pharmaceuticals in the lower half of its industry. The industry median Forward PE Ratio is 22.00. Alnylam Pharmaceuticals' value of 38.33 is 74.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.00, based on 353 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alnylam Pharmaceuticals's current Forward PE Ratio of 38.33 is 74.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Alnylam Pharmaceuticals and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alnylam Pharmaceuticals's current Forward PE Ratio is 38.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $526.23, compared to a current price of $272.24 — trading 48.3% below its estimated fair value. The current Forward PE Ratio is 38.33 and 74.2% above the Biotechnology industry median of 22.00. Alnylam Pharmaceuticals' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current Forward PE Ratio is 38.33 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued.
The current stock price of $272.24 is trading 48.3% below its estimated GF Value™ of $526.23.
GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for LTS:0HD2:
Forward PE Ratio: 38.33
GF Value™: $526.23 vs. price of $272.24 (48.3% below fair value)
Industry Position: 74.2% above the Biotechnology median (#234 of 353)
No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
62GF Score
Get the complete analysis for LTS:0HD2
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HD2 has been successfully added to your 
